At MDS 2025, the chairman and CEO at ABLi Therapeutics discussed phase 2 results of risvodetinib, a highly selective c-Abl inhibitor, in patients with Parkinson disease. [WATCH TIME: 5 minutes]
Milton Werner, PhD
Advertisement
Chairman and CEO at ABLi Therapeutics.
Articles by Milton Werner, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease
2
BridgeBio Pursues FDA Submission for BBP-418 in LGMD2i/R9 After Positive Topline Phase 3 Results
3
Evaluating the Perspectives of Caretakers and Patients with MSA
4
Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS
5
